Company: GRCE
Filing Date: 2025-08-12
Form Type: 10-Q
Source: 0001140361-25-030398
Chunk: 9

Company: Grace Therapeutics, Inc.
Filing Date: 2025-08-12
Form: 10-Q
Item: Item 8
Chunk 9
---
, and will expire on the earlier of (i) the 60th day
after the date of the acceptance by the FDA of an NDA for the Company’s product
candidate GTx-104 or (ii) five years from the date of issuance. The 2023
Private Placement closed on September 25, 2023. The net proceeds to the Company
from the 2023 Private Placement were $7,338, after deducting fees and expenses. 
   The 2023 Private Placement included the issuance of Common Shares, 2023 Pre-Funded Warrants, and 2023 Common Warrants to related parties namely (i) Shore Pharma LLC, an entity that was controlled by Vimal Kavuru, the Chair of the Company’s Board of Directors, at the time of the 2023 Private Placement and (ii) SS Pharma LLC, the beneficial owner of 5.5% of Common Shares outstanding prior to the 2023 Private Placement, resulting in proceeds of $2,500 in 2023.  There were no 2023 Common Warrants exercised during the three months ended June 30, 2025 and 2024.  The following table summarizes the Company’s
outstanding warrants as at June 30, 2025, all of which are exercisable for
shares of Common Stock: 

      June 30, 2025

      No. of warrants

      Exercise Price ($)

      Expiration Date

      Liability classified warrants (Derivative Warrant Liabilities)

      Common warrants issued in connection with 2023 Private Placement (2023 Common Warrants)

     2,536,391  
     3.003  
     1 

      Equity classified warrants

      Pre-funded warrants issued in connection with 2023 Private Placement (2023 Pre-Funded Warrants)

     1,065,002  
     0.0001  

      No expiration

      Common warrants issued in connection with 2025 Private Placement (2025 Common Warrants)

     4,418,292  
     3.395  
     2 

      Pre-funded warrants issued in connection with 2025 Private Placement (2025 Pre-Funded Warrants)

     1,030,958  
     0.0001  

      No expiration

     1. 
     The 2023 Common Warrants will expire on the earlier of (i) the